S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
NASDAQ:HZNP

Horizon Therapeutics Public (HZNP) Stock Forecast, Price & News

$115.60
+0.09 (+0.08%)
(As of 09/20/2023 ET)
Compare
Today's Range
$115.44
$115.66
50-Day Range
$98.98
$115.60
52-Week Range
$60.03
$115.70
Volume
1.51 million shs
Average Volume
3.76 million shs
Market Capitalization
$26.47 billion
P/E Ratio
61.82
Dividend Yield
N/A
Price Target
$110.71

Horizon Therapeutics Public MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
4.2% Downside
$110.71 Price Target
Short Interest
Bearish
4.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.38mentions of Horizon Therapeutics Public in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
42.19%
From $4.29 to $6.10 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

782nd out of 961 stocks

Pharmaceutical Preparations Industry

368th out of 453 stocks


HZNP stock logo

About Horizon Therapeutics Public (NASDAQ:HZNP) Stock

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

HZNP Price History

HZNP Stock News Headlines

3 Growth Stocks to Buy in September (HZNP)
As the calendar turns to September, optimistic investors will look for value in quality companies with a history of generating strong revenue and earnings
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks? (HZNP)
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Improved Outlook For Horizon Therapeutics And Amgen
Horizon Therapeutics (HZNP) Receives a Hold from H.C. Wainwright
Amgen raises full-year earnings and revenue outlook
Check Out What Whales Are Doing With HZNP
See More Headlines
Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Company Calendar

Last Earnings
8/08/2023
Today
9/21/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:HZNP
CUSIP
44047T10
Employees
2,115
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$110.71
High Stock Price Forecast
$125.00
Low Stock Price Forecast
$74.00
Forecasted Upside/Downside
-4.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
8 Analysts

Profitability

Net Income
$521.48 million
Pretax Margin
12.18%

Debt

Sales & Book Value

Annual Sales
$3.63 billion
Cash Flow
$7.07 per share
Book Value
$22.38 per share

Miscellaneous

Free Float
223,957,000
Market Cap
$26.47 billion
Optionable
Optionable
Beta
1.05

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Timothy P. WalbertMr. Timothy P. Walbert (Age 56)
    Chairman, Pres & CEO
    Comp: $3.5M
  • Mr. Aaron L. CoxMr. Aaron L. Cox (Age 40)
    Exec. VP of Fin. & CFO
    Comp: $1.36M
  • Mr. Sean M. Clayton J.D.Mr. Sean M. Clayton J.D. (Age 44)
    Exec. VP & Gen. Counsel
    Comp: $7.03M
  • Mr. Andy PasternakMr. Andy Pasternak (Age 52)
    Exec. VP & Chief Strategy Officer
    Comp: $1.4M
  • Dr. Elizabeth H.Z. Thompson Ph.D.Dr. Elizabeth H.Z. Thompson Ph.D. (Age 48)
    Exec. VP of R&D
    Comp: $3.66M
  • Mr. Patrick McIlvenny (Age 44)
    Sr. VP & Chief Accounting Officer
  • Ms. Tina E. Ventura
    Sr. VP & Chief Investor Relations Officer
  • Mr. Geoffrey M. CurtisMr. Geoffrey M. Curtis (Age 48)
    Exec. VP of Corp. Affairs & Chief Communications Officer
  • Ms. Keli Walbert
    Exec. VP & Chief Marketing Officer
  • Ms. Jane Gonnerman
    Sr. VP of Corp. Devel. & Chief of Staff, Office of the CEO













HZNP Stock - Frequently Asked Questions

Should I buy or sell Horizon Therapeutics Public stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 8 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
View HZNP analyst ratings
or view top-rated stocks.

What is Horizon Therapeutics Public's stock price forecast for 2023?

8 brokerages have issued 12 month price targets for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $74.00 to $125.00. On average, they anticipate the company's stock price to reach $110.71 in the next year. This suggests that the stock has a possible downside of 4.2%.
View analysts price targets for HZNP
or view top-rated stocks among Wall Street analysts.

How have HZNP shares performed in 2023?

Horizon Therapeutics Public's stock was trading at $113.80 at the start of the year. Since then, HZNP stock has increased by 1.6% and is now trading at $115.60.
View the best growth stocks for 2023 here
.

Are investors shorting Horizon Therapeutics Public?

Horizon Therapeutics Public saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 9,480,000 shares, an increase of 20.6% from the August 15th total of 7,860,000 shares. Based on an average daily volume of 2,300,000 shares, the days-to-cover ratio is presently 4.1 days.
View Horizon Therapeutics Public's Short Interest
.

When is Horizon Therapeutics Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our HZNP earnings forecast
.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $0.08. The biopharmaceutical company earned $945 million during the quarter, compared to analysts' expectations of $873.52 million. Horizon Therapeutics Public had a net margin of 12.02% and a trailing twelve-month return on equity of 20.46%. The company's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.07 earnings per share.

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.51%), Bluefin Capital Management LLC (0.00%), State Street Corp (2.30%), Maven Securities LTD (0.00%), Renaissance Technologies LLC (1.51%) and Soros Fund Management LLC (1.44%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends
.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $115.60.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $26.47 billion and generates $3.63 billion in revenue each year. The biopharmaceutical company earns $521.48 million in net income (profit) each year or $1.87 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

The company employs 2,115 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?
The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..
Read More
How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001.

This page (NASDAQ:HZNP) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -